“Immunotherapy Bridge 2018”
Naples – November 28th-29th 2018

PRELIMINARY PROGRAM

**Not included in the CME accredited program
*invited/to be invited faculty

November 28th (Wednesday)

08:30  09:00   Registration**
09:00  09:15   Introduction and objectives, Paolo A. Ascierto

SITC Session - Evolving topics in cancer immunotherapy: tumor microenvironment
Chairperson: Lisa H. Butterfield

09:15  09:35   Reprogramming the tumor microenvironment and t-cells for immunotherapy of ovarian cancer, Adekunle Odunsi
09:35  09:55   The contribution of tumor-residing dendritic cells to an anti-tumor immune response, Stefani Spranger
09:55  10:15   Understanding the immune composition and therapeutic implications of human lung Cancer, Kurt A. Shalper
10:15  10:35   Effectors and the TME, Chrystal Paulos
10:35  10:55   Overcoming metabolic barriers to effective antitumor immunity, Greg Delgoffe
10:55  11:15   Discussion on evolving topics in cancer immunotherapy: tumor microenvironment, Lisa H. Butterfield
11:15  11:30   Break**
11:30  12:15   Oral Communications**
12:15  12:45   Lecture - New landscapes in urothelial carcinoma**, Andrea Necchi
   Discussion on new landscapes in urothelial carcinoma**; Giacomo Carteni, Sandro Pignata
   Sponsored by MSD
12:45  13:30   Lunch**
Session - Trends in Immunotherapy

Chairpersons: Igor Puzanov, Heinz Zwierzina

13:30 14:30 Symposium – News in Immunotherapy GU and Neck
   Chairperson: Paolo A. Ascierto
   13:30 Introduction, Paolo A. Ascierto
   13:40 Immunotherapy in the neck: what’s new, Marco Merlano
   14:00 Immunotherapy in GU: what’s new, Paul Nathan
   14:20 Discussion

14:30 14:50 Immunotherapy for ovarian cancer. How to move forward, Sandro Pignata
14:50 15:10 Immunotherapy: turning up the heat on breast cancer, Leisha Emens
15:10 15:40 Immunotherapy in pancreatic cancer: lights and shadows, Giampaolo Tortora
15:40 16:00 Immunotherapy for Brain Cancer, Hideho Okada
16:00 16:15 Discussion on trends in immunotherapy, Igor Puzanov, Heinz Zwierzina
16:15 16:30 Break**
16:30 17:00 Lecture – Immunotherapy evolution for lung carcinoma, Speaker to be defined
17:00 17:30 Lecture – Immunotherapy for merkel cell carcinoma: present and future, Paolo A. Ascierto
17:30 18:15 Oral Communications**
18:15 18:30 Conclusions, Igor Puzanov, Heinz Zwierzina

November 29th (Thursday)

Session - Drivers of immune responses

Chairpersons: Carlo Bifulco, Luigi Buonaguro

09:00 09:20 Metabolic properties of immune cells in renal cell carcinoma: opportunities for therapeutic optimization, Kimryn Rathmel
09:20 09:40 Cancer vaccines and strategy to develop combination immunotherapy with T cell agonist, Bernard Fox
09:40 10:00 Next target for immune checkpoint blockade in melanoma, Hassane Zarour
10:00 10:20 Integration of immunotherapy into standard head and neck cancer management, Robert Ferris
10:20 11:40 System immunology and tumor microenvironment, Jerome Galon*
10:40 10:55 Discussion on drivers of immune responses, Carlo Bifulco, Luigi Buonaguro
10:55  11:10  Break**
11:10  12:10  Symposium - Immunotherapy in non-melanoma skin cancer: updates and new perspective
  Chairperson: Paolo A. Ascierto
  11:10  Overview on non-melanoma skin cancer, Paolo A. Ascierto
  11:30  CSCC updates and new perspective on treatment, Dirk Schadendorf
  11:50  Discussion
12:10  13:10  Oral Communications**
13:10  13:55  Lunch**

Great debate
Chairperson: Paolo A. Ascierto

13:55  14:25  Adaptive vs innate - Gordon Freeman, Alberto Mantovani
14:25  14:35  Discussion on Adaptive vs innate, Paolo A. Ascierto, Gordon Freeman, Alberto Mantovani
14:35  15:05  Combination vs sequencing - Paul Nathan, Howard Kaufman
15:05  15:15  Discussion on Combination vs sequencing, Paolo A. Ascierto, Paul Nathan, Howard Kaufman
15:15  15:45  Preclinical models: mouse vs human - Roger Lo, Omid Hamid
15:45  15:55  Discussion on preclinical models: mouse vs human, Paolo A. Ascierto, Roger Lo, Omid Hamid
15:55  16:25  Is resistance different in different cancers? Yes or no, Sandra Demaria, Katerina Politi
16:25  16:35  Discussion on Is resistance different in different cancers? Paolo A. Ascierto, Sandra Demaria, Katerina Politi
16:35  16:55  Conclusions, Paolo A. Ascierto, Lisa H. Butterfield, Igor Puzanov
16:55  17:55  Immune responsiveness task force**
  Paolo A. Ascierto, Franco Marincola, Stefani Spranger, Alessandra Cesano
Presidency

Paolo A. Ascierto  
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Lisa H. Butterfield  
Professor of Medicine, Surgery, Immunology and Clinical and Translational Science.  
Director, Immunologic Monitoring and Cellular Products Laboratory  
University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA

Igor Puzanov  
Associate Professor of Medicine, Associate Director of Phase I Drug Development,  
Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Scientific Board

Sanjiv Agarwala  
Chief of Medical oncology and Haematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto  
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Carlo Bifulco  
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Lisa H. Butterfield  
Professor of Medicine, Surgery, Immunology and Clinical and Translational Science.  
Director, Immunologic Monitoring and Cellular Products Laboratory  
University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA

Corrado Caracò  
Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Reinhard Dummer  
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox  
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon  
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe  
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Giuseppe Masucci  
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Michael Postow  
Memorial Sloane Kettering Cancer Center, New York, New York

Igor Puzanov  
Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Magdalena Thurin  
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Invited Faculty
Paolo A. Ascierto  Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Fabrice Barlesi  Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, Coordinator of the Center of Early Phase Cancer Trials of Marseille CLIP2, Professor of Medicine at Aix-Marseille University, Marseille, France

Carlo Bifulco  Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Luigi Buonaguro  Unit of Molecular Biology and Viral Oncology, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Lisa H. Butterfield  Professor of Medicine, Surgery, Immunology and Clinical and Translational Science. Director, Immunologic Monitoring and Cellular Products Laboratory University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA

Giacomo Cartení  Director of Medical Oncology Unit A. Cardarelli Hospital, Naples, Italy

Greg Delgoffe  Department of Immunology, University of Pittsburgh, Pittsburgh, PA

Sandra Demaria  New York University School of Medicine and NYU Langone Medical Center Alexandria Center for Life Sciences, New York, New York

Leisha Emens  Johns Hopkins University School of Medicine, Oncology, Baltimore, Maryland, US

Robert Ferris  UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh, Pennsylvania, US

Bernard A. Fox  Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Gordon Freeman  Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, US

Jerome Galon  Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Howard Kaufman  Professor of Surgery, Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Jersey, US

Omid Hamid  Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, Los Angeles, CA

Roger Lo  Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California, US

Alberto Mantovani  Scientific Director IRCCS Humanitas, Professor of General Pathology, “Humanitas University”, Rozzano (MI), Italy

Marco Merlano  Director of Medical Oncology Unit, S. Croce and Carle Hospital, Cuneo, Italy

Paul Nathan  Consultant Medical Oncologist, Mount Vernon Cancer Centre, Northwood, Middlesex, UK

Andrea Necchi  Medical Oncology Unit, IRCCS Foundation, National Cancer Institute, Milan, Italy
Adeakunle Odunsi  Chair, Department of Gynecologic Oncology, The M. Steven Piver Professor of Gynecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer, Buffalo, New York, US

Hideho Okada  Cancer Immunotherapy Program, University of California San Francisco, San Francisco, CA, US

Chrystal Paulos  ITC, Medical University of South Carolina, US

Sandro Pignata  National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Katerina Politi  Department of Pathology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Igor Puzanov  Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Kimryn Rathmel  Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, US

Dirk Schadendorf  Director Clinic for Dermatology, Essen University Hospital, Essen, Germany

Kurt Schalper  Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut. Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, US

Stefani Spranger  The Koch Institute for Integrative Cancer Research at MIT and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, US

Giampaolo Tortora  Professor, Surgical and Medical School, Verona University, Verona, Italy

Hassane Zarour  Professor of Medicine, Immunology and Dermatology, Co-Leader, Melanoma Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania, US

Heinz Zwierzina  Chairman of the CDDF – Cancer Drug Development Forum and Professor of Internal Medicine at Innsbruck University in Austria
SCIENTIFIC RATIONAL

After decades when most immunotherapeutic approaches used to fight cancer seemed ineffective, counteracted by the tumor’s ability to evade immune attack, extensive research has improved our understanding of tumor immunology and enabled the development of treatments that can harness the patient’s immune system and prevent immune escape.

The relative recent clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitors in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. Indeed, it has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The first session of immunotherapy bridge will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC) and dedicated to the evolving topics on cancer immunotherapy and tumor microenvironment. A focus on the trends in immunotherapy in various type of cancers (e.g. pancreas, central nervous system) and on the drivers of immune response (e.g. the role of metabolism) will follow.

Conclusions will be drawn after the “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed: (1) adaptive versus innate immunotherapeutic approaches; (2) combined versus sequential administration of immunotherapeutic treatments; (3) mouse versus human as preclinical models; (4) whether resistance is different in different cancers.

Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Lisa Butterfield (University of Pittsburgh, Pennsylvania) and Igor Puzanov (Roswell Park Cancer Institute in Buffalo New York) and will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience on the immunotherapy of cancer.